Exact Sciences is paying $75 million for exclusive rights to a blood-based "liquid biopsy" screening test from rival firm ...

Exact Sciences (NASDAQ:EXAS) said it has secured exclusive rights to both current and future iterations of Freenome’s ...

Exact Sciences stock crashed Thursday as the Street debated the merits of its licensing deal for a blood-based colon cancer ...

Exact Sciences Corp. (NYSE:EXAS) on Thursday reported a second-quarter 2025 EPS loss of 1 cent, up from a 9-cent loss a year ...

The layoffs come despite CEO Kevin Conroy telling investors the company had just completed an “unbelievable quarter” for the ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, and Freenome, a ...

Brisbane, California Friday, August 8, 2025, 10:00 Hrs [IST] ...

Freenome is conducting the PREEMPT CRC study, a >35,000-person prospective study for colorectal cancer (CRC) evaluating Freenome's blood-based screening test for CRC in the average-risk population.

Freenome and the U.S. Food and Drug Administration agreed upon a predetermined cut-off date for the period most affected by the COVID-19 pandemic. Of the 48,995 participants enrolled, 27,010 were ...

Blood test developer Freenome said on Thursday it has raised $254 million in a new funding round led by Swiss drugmaker Roche, to develop tests that can potentially detect multiple early-stage ...

Freenome's existing investors also participated in the financing, including RA Capital Management, funds and accounts advised by T. Rowe Price Associates, Inc., American Cancer Society’s ...